Osimertinib in adjuvant treatment EGFR+ non‑small cell lung cancer – ADAURA trial

05/2021

MUDr. Ondřej Bílek

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

SUMMARY

Approximately one-quarter of patients with non-small cell lung cancer are diagnosed with early or locally advanced stage of the disease suitable for surgery. There is a high risk of disease recurrence after adjuvant chemotherapy. The ADAURA trial demonstrated a significant benefit of adjuvant treatment with osimertinib in patients with non-small cell lung cancer with evidence of aberration of EGFR del19 or L858R in exon 21.

Key words

Non-small cell lung cancer, EGFR, osimertinib